Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs ConocoPhillips (COP) Price & Performance

Bristol-Myers Squibb CoTrade
ConocoPhillipsTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs ConocoPhillips — how do they compare? Bristol-Myers Squibb Co trades at $63.81 (market cap $132.45B), while ConocoPhillips trades at $125.89 (market cap $147.80B). The key difference: Bristol-Myers Squibb Co and ConocoPhillips are close in size by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.

BMYCOP
Market Cap
$132.45B$147.80B
Sector
HealthEnergy
52-Week High
$65.89$133.80
52-Week Low
$42.60$85.66
Enterprise Value
$166.44B$163.40B
Dividend Yield
3.89%2.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.

BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.

ConocoPhillips

ConocoPhillips (COP) trades at $117.61, up 0.73% today, with a bullish technical signal from moving averages and a consensus analyst price target of $149.25. Recent Q2 2026 earnings beat expectations with EPS of $3.24 versus $2.90 estimated, driven by strong Permian Basin output and higher oil prices. The company reaffirmed its $7 billion free cash flow target by 2029 and completed a $1.7 billion asset sale ahead of schedule.

Outlook is positive due to robust operational performance and favorable oil market trends, but risks include commodity price volatility and CEO transition. The stock offers value with a P/E of 15.56 and a net income margin of 14.65%, supported by 74.51% analyst buy ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About ConocoPhillips

ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.

Read more on COP